Biotherapeutic antibodies for the treatment of head and neck cancer : current approaches and future considerations of photothermal therapies

Tools

Al Qaraghuli, Mohammed M. (2020) Biotherapeutic antibodies for the treatment of head and neck cancer : current approaches and future considerations of photothermal therapies. Frontiers in Oncology, 10. 559596. ISSN 2234-943X (https://doi.org/10.3389/fonc.2020.559596)

[thumbnail of Al-Qaraghuli-FO-2020-Biotherapeutic-antibodies-for-the-treatment-of-head-and-neck-cancer]
Preview
 Text. Filename: Al_Qaraghuli_FO_2020_Biotherapeutic_antibodies_for_the_treatment_of_head_and_neck_cancer.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (3MB)| Preview

Abstract

Head and neck cancer (HNC) is a heterogeneous disease that includes a variety of tumors originating in the hypopharynx, oropharynx, lip, oral cavity, nasopharynx, or larynx. HNC is the sixth most common malignancy worldwide and affects thousands of people in terms of incidence and mortality. Various factors can trigger the development of the disease such as smoking, alcohol consumption, and repetitive viral infections. HNC is currently treated by single or multimodality approaches, which are based on surgery, radiotherapy, chemotherapy, and biotherapeutic antibodies. The latter approach will be the focus of this article. There are currently three approved antibodies against HNCs (cetuximab, nivolumab, and pembrolizumab), and 48 antibodies under development. The majority of these antibodies are of humanized (23 antibodies) or human (19 antibodies) origins, and subclass IgG1 represents a total of 32 antibodies. In addition, three antibody drug conjugates (ADCs: telisotuzumab-vedotin, indatuximab-ravtansine, and W0101) and two bispecific antibodies (GBR 1372 and ABL001) have been under development. Despite the remarkable success of antibodies in treating different tumors, success was limited in HNCs. This limitation is attributed to efficacy, resistance, and the appearance of various side effects. However, the efficacy of these antibodies could be enhanced through conjugation to gold nanoparticles (GNPs). These conjugates combine the high specificity of antibodies with unique spectral properties of GNPs to generate a treatment approach known as photothermal therapy. This approach can provide promising outcomes due to the ability of GNPs to convert light into heat, which can specifically destroy cancer cells and treat HNC in an effective manner.

ORCID iDs

Al Qaraghuli, Mohammed M. ORCID logoORCID: https://orcid.org/0000-0003-1823-6671;
CORE (COnnecting REpositories)